The report of Global Conjunctivitis Drugs Market of Market Research Future comprises extensive
primary research along with the detail analysis of qualitative as well as quantitative aspects by various
industry experts and key opinion leaders to gain a deeper insight of the market and industry
performance. Conjunctivitis, or pink eye, is inflammation of the outermost layer of the white part of the
eye and the inner surface of the eyelid due to numerous causes the most common being bacterial
infection. The condition is self-limiting, but in some cases results in kerato-conjunctivitis, which results
in blurred vision. The viral and bacterial conjunctivitis results in highly infectious watery discharge
which is extremely contagious.
The market for conjunctivitis is growing at a moderate rate. The growth factors for the growth of global
conjunctivitis drugs market are rise in hygiene and awareness, growing expenditure on health, greater
exposure to allergens and infective agents, the contagious nature of the disease etc. However the
market is restrained by many factors such as the self-limiting nature of the disease, off label drug use,
greater fragmentation of the market and penetration of generics etc. However the most important
reason is loss of patents on a number of market leaders such as Moxeza, Besivance, Vigamox, and
Zymaxid. The lack of specific treatment for allergic conjunctivitis and self-limiting and non-life
threatening nature of the treatment also acts as a constraint.
Taking all these factors together, we expect the Global Conjunctivitis Drugs Market to reach around
US$ 1.08 billion by the end of the forecast period and is expected to grow at a CAGR of ~3.1%.
Study Objectives Global Conjunctivitis Drugs Market:
To provide detail analysis of the market structure along with forecast for the next 7 years of
various segments and sub-segments of the global conjunctivitis drugs market.
To provide insights about factors affecting the market growth.
To analyze the market based on various analyses which includes price analysis, supply
chain analysis, Porters Five Force analysis etc.
To provide past and estimated future revenue of the market’s segments and sub-segments
with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific,
and Middle East & Africa.
To provide country level analysis of the market with respect to the current market size and
future growth prospect.
To provide country level analysis of the market for segments which includes by conjunctivitis
type, by drug class, by route of administration, by end users and other sub segments.
To provide overview of key players and their strategic profiling in the market,
comprehensively analyzing their core competencies and drawing a competitive landscape for
the market
To track and analyze competitive developments such as joint ventures, strategic alliances,
mergers and acquisitions, new product developments along with global research and
developments.